The use of the anti-CD20 antibody rituximab has improved the outcome of patients with
chronic lymphocytic leukemia (CLL). Rituximab was shown to act via various mechanisms …

Rituximab is a class I chimeric anti-CD20 antibody that has shown efficacy in chronic
lymphocytic leukemia (CLL), both as a single agent and in combination with traditional …

Abstract Rituximab (Rituxan®; iogen Idec, San Diego, CA, USA) is a human-mouse chimeric
monoclonal antibody specific for CD20, a surface glycoprotein expressed on B lymphocytes …

Objectives: This prospective multicentre study was conducted to assess the efficacy of the
monoclonal anti‐CD20 antibody rituximab in patients with chronic lymphocytic leukaemia …

A pilot study previously demonstrated that thrice-weekly, fractionated-dose intravenous
rituximab (RTX) limits CD20 loss from chronic lymphocytic leukemia (CLL) B cells, thereby …

PURPOSE: To conduct a dose-escalation trial of rituximab in patients with chronic
lymphocytic leukemia (CLL) to define the maximum-tolerated dose (MTD), to evaluate first …

Rituximab (IDEC-C2B8) is a chimeric antibody that binds to the B-cell surface antigen CD20.
Rituximab has significant activity in follicular non-Hodgkin lymphomas. Much less is known …

Introduction: Rituximab is a high-affinity chimeric mouse anti-CD20 monoclonal antibody,
currently used for the treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocytic …

Rituximab (IDEC C2B8) is a chimeric human-mouse monoclonal anti-CD20 antibody that
has been proven to be effective for the treatment of patients with CD20 positive leukemia …

Complement plays an important role in the immunotherapeutic action of the anti-CD20 mAb
rituximab, and therefore we investigated whether complement might be the limiting factor in …